Treatment for Cataract

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Waring Vision Institute, Mount Pleasant, SC
Cataract
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Tecnis Symfony Optiblue (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus intraocular lens (IOL) that provides a continuous range of clear vision at far and intermediate. Tecnis Synergy™ IOL (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles. These IOLs are approved/licensed for use and are not investigational. The present study intends to evaluate the clinical outcomes and patient satisfaction following contralateral implantation of Tecnis Synergy and Symfony Optiblue in cataract patients. The investigator hypothesizes that the contralateral implantation of these two lenses will allow a good proportion of patients to be spectacle independent at distance, intermediate, and near. The findings of this study may help the surgeons make better decisions on the choice of IOL in the future.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 6 Secondary · Reporting Duration: Postoperative 3 months

Postoperative 3 months
Binocular distance-corrected intermediate visual acuity under mesopic conditions
Binocular distance-corrected intermediate visual acuity under photopic conditions.
Binocular distance-corrected near visual acuity under mesopic conditions
Binocular distance-corrected near visual acuity under photopic conditions.
Binocular distance-corrected very near visual acuity under mesopic conditions
Binocular distance-corrected very near visual acuity under photopic conditions.
Binocular uncorrected distance visual acuity under mesopic conditions
Binocular uncorrected distance visual acuity under photopic conditions
Binocular uncorrected intermediate visual acuity under mesopic conditions
Binocular uncorrected intermediate visual acuity under photopic conditions
Binocular uncorrected near visual acuity under mesopic conditions
Binocular uncorrected near visual acuity under photopic conditions
Binocular uncorrected very near visual acuity under mesopic conditions
Binocular uncorrected very near visual acuity under photopic conditions
Subjective assessment of patient satisfaction and other patient-reported outcomes using spectacle independence questionnaire (PRSIQ)
Subjective assessment of patient satisfaction and other patient-reported outcomes using visual symptoms questionnaire (PRVSQ)

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

30 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: postoperative 3 months
Closest Location: Waring Vision Institute · Mount Pleasant, SC
Photo of south carolina 1Photo of south carolina 2Photo of south carolina 3
2020First Recorded Clinical Trial
1 TrialsResearching Cataract
1 CompletedClinical Trials

Who is running the clinical trial?

Johnson & Johnson Surgical Vision, Inc.Industry Sponsor
27 Previous Clinical Trials
7,401 Total Patients Enrolled
23 Trials studying Cataract
6,797 Patients Enrolled for Cataract
George O. Waring IVLead Sponsor
George O Waring IV, MD FACSPrincipal InvestigatorWaring Vision Institute

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
The patient is a suitable candidate for Tecnis IOLs.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.